COPD

Pharma

After trial fail, Teravance is bought out by Zymeworks for $929M

Four months after Theravance Biopharma signaled it was up for sale, the Dublin-based company has agreed to be bought out by Zymeworks for $929 million.

Kevin Dunleavy Jun 29, 2026 11:30am

Merck reports mixed results in Q1 for Winrevair, Ohtuvayre

Apr 30, 2026 11:40am

AZ's Breztri picks up 2nd FDA nod, unlocking asthma market

Apr 28, 2026 10:47am

Insmed forecasts sales of Brinsupri will reach $1B in 2026

Feb 19, 2026 11:45am

Merck pays $10B to acquire Verona and COPD drug Ohtuvayre

Jul 9, 2025 11:25am

COPD chronic obstructive pulmonary disease lungs

GSK revs up launch plans after Nucala's FDA approval in COPD

May 22, 2025 3:10pm